This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Participant must be ≥ 18 years of age.
Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Parts 2A, 1D, 2D: ccRCC.
Untreated central nervous system (CNS) metastases.
Leptomeningeal metastasis (carcinomatous meningitis).
Impaired cardiac function or clinically significant cardiac disease.
For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.
8
Treatment groupsSee each treatment group below.